You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The informatics company will apply AI to genomic and phenotypic data in hopes of identifying people at highest risk of contracting COVID-19.
The early-stage company just launched a bioinformatics security service, but it is developing technology to label and manage individual molecules in DNA samples.
A new partnership between Microsoft, the Broad, and Verily Life Sciences aims to improve collaboration among Terra users worldwide.
The Dutch bioinformatics firm's ImmunoGenomiX technology platform is helping researchers develop therapies for COVID-19 as well as for cancer.
Some are comparing iGenomics, a former high school intern's creation, to the fictional "medical tricorder" of "Star Trek" fame.
Through this partnership, the companies hope to help oncologists make better testing and treatment decisions, as well as improve clinical trial matching.
By chopping RNA-seq reads into smaller bits, UW-Tacoma data scientists are able to cut the alignment step to one minute, but the approach has skeptics.
San Francisco Otolaryngology hopes that 2bPrecise's PGx technology can help manage the medication burden on older patients and improve symptoms of dementia.
With its recent $50 million VC round, the British bioinformatics firm is targeting growth in new applications as it accelerates tertiary data analysis.
The partners will apply whole-exome and whole-transcriptome analysis to evaluate two existing drugs for squamous cell carcinoma treatment.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.